查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1138319

脂质体阿霉素的全球市场-2022-2029

Global Liposomal Doxorubicin Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 180 Pages | 商品交期: 约2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场动态

全球脂质体阿霉素市场的增长是由全球癌症发病率上升和製造阿霉素的公司数量不断增加推动的。

全球癌症发病率上升，生产阿霉素的公司越来越多

预计越来越多的公司生产阿霉素将推动市场增长。

癌症患者数量的增加正在推动脂质体阿霉素的全球市场。例如，根据世界卫生组织 (WHO) 的数据，癌症每年占全球死亡人数的 13%。此外，预计未来几十年癌症发病率将增加 70%，预计 2015 年至 2022 年期间，世界老年人口将增加近一倍，从 12% 增加到 22%。事实已经如此。从 2015 年到 2030 年，全球各类癌症的发病率预计将以 2.5% 的复合年增长率增长。预计癌症死亡率的增长速度将高于发病率，2015-2030 年的复合年增长率为 2.6%。

製造商增加产品开发和新参与者进入市场也有望在预测期内推动市场增长。例如，2019 年 3 月，Cytori Therapeutics, Inc. 向欧洲医疗机构（EMA）提交了盐酸阿霉素 Cytori 的正式上市前申请。该申请是 EMA 集中审批流程下第 58 条申请上市许可申请 (MAA) 的前身。

与阿霉素相关的副作用预计会阻碍市场增长。

与脂质体阿霉素相关的一些副作用预计会在预测期内阻碍市场增长。一些副作用包括感染风险增加、气短或肤色苍白、瘀伤、牙龈出血、流鼻血、疲倦或虚弱（疲劳）在治疗期间或治疗后、手脚疼痛、发红、皮肤。脱皮、厌食和体重减轻、腹泻和便秘。

行业分析

全球脂质体阿霉素市场根据波特五力分析、流行病学、监管分析、供应链分析、产品创新和未满足的需求等各种行业因素对市场进行深入分析。

全球脂质体阿霉素市场报告将提供对大约 45 多个市场数据表、40 多个数字和 180 页的访问。

内容

第一章研究方法与范围

  • 调查方法
  • 调查目的和范围

第 2 章市场定义和概述

第 3 章执行摘要

第 4 章市场动态

  • 市场影响因素
    • 驱动程序
      • 全球癌症发病率上升，阿霉素製造商数量增加
    • 限制因素
      • 与阿霉素相关的副作用
    • 商机
    • 影响分析

第五章行业分析

  • 波特五力分析
  • 流行病学
  • 监管分析
  • 供应链分析
  • 产品创新
  • 未满足的需求

第 6 章按产品分类

  • Doxyl/Cailex
  • Lipodox
  • 米奥塞特
  • 其他

第 7 章按配方

  • 冻干粉
  • 阿霉素注射液

第 8 章按应用程序

  • 卡波西肉瘤
  • 白血病
  • 乳腺癌
  • 卵巢癌
  • 多发性骨髓瘤
  • 子宫内膜癌
  • 肝癌
  • 骨肉瘤
  • 肾癌
  • 其他

第 9 章分销渠道

  • 医院药房
  • 零售药房
  • 在线药店

第 10 章按地区划分

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 意大利
    • 西班牙
    • 其他欧洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 其他亚太地区
  • 中东和非洲

第 11 章竞争格局

  • 主要发展和战略
  • 公司份额分析
  • 产品基准
  • 值得关注的重点公司列表

第 12 章公司简介

  • Pfizer Inc.
    • 公司概况
    • 产品组合和描述
    • 主要亮点
    • 财务摘要
  • SRS Pharmaceuticals Pvt. Ltd.
  • Johnson & Johnson
  • Sun Pharmaceutical Industries Ltd.
  • Cadila Pharmaceuticals
  • Merck & Co.
  • Cipla, Inc.

第13章 脂质体阿霉素世界市场-DataM

简介目录
Product Code: DMPH2194

Market Overview

Liposomal doxorubicin Market size was valued US$ 1,160 million in 2022 and is estimated to reach US$ 2 billion by 2029, growing at a CAGR of 6.2 % during the forecast period (2022-2029).

Liposomal Doxorubicin is a chemotherapy drug-containing doxorubicin (Adriamycin) wrapped up in a fatty covering called a liposome. Doxorubicin blocks an enzyme called topoisomerase 2 that cancer cells need to divide and grow. Liposomal doxorubicin is doxorubicin contained in tiny spheres called pegylated liposomes. These spheres keep the doxorubicin in the bloodstream longer so that more of the drug reaches the cancer cells. It is used to treat several types of cancer, including breast cancer, ovarian cancer, Kaposi's sarcoma, and multiple myeloma.

Market Dynamics

The global liposomal doxorubicin market growth is driven by the surge in prevalence of cancer globally and Increasing number of companies manufacturing doxorubicin.

The rising prevalence of cancer globally and Increasing number of companies

manufacturing doxorubicin are expected to drive market growth.

The rising number of cancer cases drives the global liposomal doxorubicin market. For instance, according to the World Health Organization (WHO), cancer accounts for 13% of deaths globally every year. Moreover, a 70% increase in cancer incidences is anticipated over the next couple of decades, and the global geriatric population is anticipated to nearly double from 12% to 22%, from 2015 to 2022. The incidence of all cancer types worldwide is anticipated to increase at a CAGR of 2.5% during 2015-2030. The mortality rate of cancers is likely to increase at a higher rate than the incidence rate during 2015-2030, at a CAGR of 2.6%.

The market growth is also estimated to boost over the forecast period due to rising product development by manufacturers and new players entering the market. For instance, in March 2019, Cytori Therapeutics, Inc. has filed a formal new drug application pre-submission request to the European Medicine Agency (EMA) for Doxorubicin Hydrochloride Cytori. This submission is the precursor to filing an Article 58 Application for a Marketing Authorization Application (MAA) via EMA's centralized approval procedure.

Side Effects associated with doxorubicin is expected to hamper the market growth.

There are some side-effects associated with liposomal doxorubicin which are expected to hamper the market's growth over the forecast period. some of the side-effects include increased risk of getting an infection, breathlessness and looking pale, bruising, bleeding gums and nosebleeds, tiredness and weakness (fatigue) during and after treatment, soreness, redness and peeling of your hands and feet, loss of appetite and weight loss, diarrhea or constipation, among others.

Industry Analysis

The global liposomal doxorubicin market provides in-depth analysis of the market based on various industry factors such as Porter's Five Forces Analysis, Epidemiology, Regulatory Analysis, Supply Chain Analysis, Product Innovations, Unmet Needs.

Segment Analysis

Doxil/Caelyx segment is expected to hold the largest market share in global liposomal doxorubicin market

The market is segmented into Doxil/Caelyx, Lipodox, Myocet, and Others based on product type. Doxil/Caelyx segment accounted for the highest market share, owing to the rising incidence of ovarian and breast cancers. The increasing demand for Doxil or Caelyx (J&J) as a second-line treatment for ovarian carcinoma is also expected to boost its growth over the forecast period. Caelyx/Doxil is a novel pegylated liposomal formulation of the first-generation anthracycline, doxorubicin. The pharmacokinetics of this polyethylene-glycol-coated liposome is characterized by a reduced volume of distribution, a long intravascular circulating half-life and slow plasma clearance compared with free doxorubicin.

By application, the liposomal doxorubicin market is segmented into Kaposi sarcoma, leukemia, breast cancer, multiple myeloma, ovarian cancer, endometrial cancer, liver cancer, bone sarcoma, kidney cancer, and others. Among these, breast cancer accounted for the highest market share in 2018, owing to rising demand for the treatment in increasing breast cancer cases globally. According to Breastcancer.org, about 1 in 8 U.S. women (about 12%) develop invasive breast cancer over the course of their lifetime. In 2019, an estimated 268,600 new cases of invasive breast cancer were expected to be diagnosed in women in the U.S., along with 62,930 new non-invasive (in situ) breast cancer cases. About 2,670 new cases of invasive breast cancer are expected to be diagnosed in men in 2019. A man's lifetime risk of breast cancer is about 1 in 883. According to the American Cancer Institute, Doxorubicin is used during advanced breast cancer treatment as a chemo drug. It is observed that 3 million women diagnosed with breast cancer are currently there in the United States. Hence, an increasing burden of breast cancer leads to a rise in demand for treatment.

Geographical Analysis

North America region holds the largest market share in the global liposomal doxorubicin market

North America is dominating the global liposomal doxorubicin market, accounting for the largest market share in 2018, owing to an increasing number of cancer cases and consequently growing demand for doxorubicin in mono and combination chemotherapies. United States is the biggest market share holder of liposomal doxorubicin development and it has been allowed to import the medicine under the exercise enforcement discretion. The huge demand of liposomal doxorubicin in the market is fueling the doxorubicin HCl liposome injections import. As of January 2019, more than 3.1 million women have a history of breast cancer in the U.S. Also, the growing number of partnerships, mergers and acquisitions for clinical trials with technologically advanced doxorubicin formulations drive the market's growth in this region.

Competitive Landscape

The liposomal doxorubicin market is highly competitive with the presence of a large number of major players. Some of the major players in the global liposomal doxorubicin market include Johnson & Johnson, SRS Pharmaceuticals Pvt. Ltd., Sun Pharmaceutical Industries Ltd., Cadila Pharmaceuticals, Merck & Co., Cipla, Inc., Pfizer Inc., among others.

The key players are adopting various growth strategies such as product launches, mergers & acquisitions, partnerships, and collaborations contributing to the growth of the liposomal doxorubicin market globally. For instance,

In January 2019, Celsion Corporation, an oncology drug development company, announced results from Phase I TARDOX trial of ThermoDox conducted at the University of Oxford, United Kingdom. The TARBOX trial evaluated the safety and efficacy of ThermoDox, Celsion's proprietary heat-activated liposomal encapsulation of doxorubicin, along with focused ultrasound for the treatment of liver cancer.

Key Companies to Watch

Pfizer Inc.

Overview: Pfizer Inc. is an American multinational pharmaceutical corporation that works in biotechnology domain also. It was founded in 1849 and headquartered in Manhattan, New York City. It is a manufacturer of various vaccines and medicines for cardiology, oncology, neurology, immunology.

Products Portfolio: NYVEPRIA: It is helpful in reducing the incidence of infection, caused by febrile neutropenia, to the patients that have non-myeloid malignancies and are getting myelosuppressive anti-cancer drugs related with a clinically notable increase of febrile neutropenia.

Key Developments: In Aug 2021, Trillium Therapeutics Inc was attained for around $2.3 billion by this company along with its immuno oncology portfolio.

The global liposomal doxorubicin market report would provide an access to an approx. 45+market data table, 40+figures and 180pages.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. The Rising prevalence of cancer globally and Increasing number of companies manufacturing doxorubicin
    • 4.1.2. Restraints:
      • 4.1.2.1. Side Effects associated with Doxorubicin
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1 Porter's Five Forces Analysis
  • 5.2 Epidemiology
  • 5.3 Regulatory Analysis
  • 5.4 Supply Chain Analysis
  • 5.5 Product Innovations
  • 5.6 Unmet Needs

6. By Product

  • 6.1. Introduction
    • 6.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
    • 6.1.2. Market Attractiveness Index, By Product Segment
  • 6.2. Doxil/Caelyx
      • 6.2.1.1. Introduction
      • 6.2.1.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 6.3. Lipodox
  • 6.4. Myocet
  • 6.5. Others

7. By Drug Formulation

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Formulation
    • 7.1.2. Market Attractiveness Index, By Drug Formulation Segment
  • 7.2. Lyophilized Powder
      • 7.2.1.1. Introduction
      • 7.2.1.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Doxorubicin Injection

8. By Application

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 8.1.2. Market Attractiveness Index, By Application Segment
  • 8.2. Kaposi Sarcoma
      • 8.2.1.1. Introduction
      • 8.2.1.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Leukemia
  • 8.4. Breast Cancer
  • 8.5. Ovarian cancer
  • 8.6. Multiple Myeloma
  • 8.7. Endometrial Cancer
  • 8.8. Liver Cancer
  • 8.9. Bone Sarcoma
  • 8.10. Kidney Cancer
  • 8.11. Others

9. By Distribution Channel

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.1.2. Market Attractiveness Index, By Distribution Channel Segment
  • 9.2. Hospital Pharmacy
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Retail Pharmacy
  • 9.4. Online Pharmacy

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
    • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Formulation
    • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.2.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.2.7.1. U.S.
      • 10.2.7.2. Canada
      • 10.2.7.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
    • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Formulation
    • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.3.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.3.7.1. Germany
      • 10.3.7.2. U.K.
      • 10.3.7.3. France
      • 10.3.7.4. Italy
      • 10.3.7.5. Spain
      • 10.3.7.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Formulation
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.7.1. Brazil
      • 10.4.7.2. Argentina
      • 10.4.7.3. Rest of South America
  • 10.5. Asia Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Formulation
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.7.1. China
      • 10.5.7.2. India
      • 10.5.7.3. Japan
      • 10.5.7.4. Australia
      • 10.5.7.5. Rest of Asia Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Formulation
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

11. Competitive Landscape

  • 11.1. Key Developments and Strategies
  • 11.2. Company Share Analysis
  • 11.3. Products Benchmarking
  • 11.4. List of Key Companies to Watch

12. Company Profiles

  • 12.1 Pfizer Inc.
    • 12.1.1 Company Overview
    • 12.1.2 Product Portfolio and Description
    • 12.1.3 Key Highlights
    • 12.1.4 Financial Overview
  • 12.2 SRS Pharmaceuticals Pvt. Ltd.
  • 12.3 Johnson & Johnson
  • 12.4 Sun Pharmaceutical Industries Ltd.
  • 12.5 Cadila Pharmaceuticals
  • 12.6 Merck & Co.
  • 12.7 Cipla, Inc.

LIST NOT EXHAUSTIVE

13. Global Liposomal Doxorubicin Market - DataM

  • 13.1. Appendix
  • 13.2. About Us and Distribution Channel
  • 13.3. Contact Us